Next Article 
Clinical and Diagnostic Laboratory Immunology, January 2001, p. 1-8, Vol. 8, No. 1
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.1.1-8.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
MINIREVIEW
Whipple's Disease
Florence
Fenollar and
Didier
Raoult*
Unité des Rickettsies, CNRS: UPRESA
6020, Faculté de Médecine, Université de la
Méditerranée, 13385 Marseille cedex 05, France
 |
INTRODUCTION |
At the beginning of the last
century, George Whipple reported a case of disease in a medical
missionary who died after suffering from chronic arthralgias, diarrhea,
weight loss, abdominal discomfort, cough, fever, hypotension, increased
skin pigmentation, and severe anemia 62. The pathologic
findings showed fat deposition in intestinal and mesenteric lymph nodes
62. Nowadays, Whipple's disease is being recognized with
increasing frequency as the result of greater awareness of the entity,
the improvement of diagnostic tools, and a possible true increase in
incidence. Patients suffering from the disease often present with
malabsorption and other gastrointestinal symptoms. However, articular,
cardiac, and central nervous system involvement is not uncommon and may
be more prominent clinically. These various manifestations reflect the
systemic nature of a chronic infection associated with rod-shaped
organisms. The traditional laboratory diagnosis is based on light
microscopy, which shows diastase-resistant, periodic acid-Schiff
(PAS)-positive, non-acid-fast granules in macrophages of intestinal
biopsy specimens. The greatest concentration of these typical foamy
macrophages, considered the hallmark of the disease, is in the mucosa
of the small intestine and regional intestinal lymph nodes, but they
have been found in a wide distribution of systemic sites, the most
common being neurologic, pulmonary, or cardiovascular. In 1991, a
portion of the 16S rRNA gene of the bacterium was sequenced by Wilson
et al. 63, allowing the classification of the Whipple's
disease bacterium within the Actinomycetes clade. One year
later, these findings were confirmed and extended by Relman et al.
50. Since then, PCR has become a useful tool for the
diagnosis of Whipple's disease 47. Culture of the
bacterium has been an elusive goal for many generations of
microbiologists 27, 55. In 2000, we reported the
successful isolation and establishment of a strain of Whipple's
disease bacterium obtained from the mitral valve of a patient with
blood culture-negative endocarditis, the generation of antibodies
against the bacterium in mice, the detection of the bacterium in the
patient's mitral valve by immunochemistry with these antibodies, and
the detection of specific antibodies against the bacterium in the
patient's serum 48. At the beginning of this century,
with the possible culture of the Whipple's disease bacterium and the
new tools such as PCR, we believe that a new area has begun for the
epidemiology and the diagnosis of Whipple's disease, accompanied by a
more complete understanding of the infection, improved therapy, and
better clinical outcomes. The past, the present, and the future of
Whipple's disease are reviewed in this article.
 |
HISTORICAL BACKGROUND |
On May 9, 1907, George Hoyt Whipple, then an instructor
in pathology at Johns Hopkins University, performed an autopsy on a
36-year-old physician who had been domiciled at Constantinople (Istanbul), Turkey 62. He presented with gradual loss of
weight and strength, stools consisting chiefly of neutral fat and fatty acids, undefined abdominal signs, and arthritis in multiple joints 62. The findings at autopsy consisted of polyserositis,
aortic valve lesions, and prominent deposition of fat within intestinal mucosa and mesenteric lymph nodes, with marked infiltration by foamy
macrophages, as well as the presence of rod-like bacilli, approximately
2 µm long, in the lamina propria of the intestine, but Whipple did
not consider the rod-like bacilli to be the etiology of the disease.
With special stains, he noted the presence of fatty acids, but not
neutral fat, and thus incorrectly concluded that the condition arose
from an abnormality of fat metabolism; hence, he coined the term
"intestinal lipodystrophy" 62. Similar pathological
findings were reported in the English literature by Allchin and Hebb,
18 years before Whipple's description, and under the name
"lymphangiectasis intestini." The similarity between these two
reports went unnoticed until 1961, when Morgan 41 reviewed
the original tissue blocks, restained the sections, and demonstrated
PAS-positive macrophages. The first demonstration that the foamy
macrophages were diastase resistant and PAS positive was by Hendrix et
al. in 1950 25. This finding of PAS-positive macrophages
filling the lamina propria of the small intestine was considered then
pathognomonic of Whipple's disease. In 1947, the first report of
Whipple's disease prior to death was reported 43. In
1952, Pauley 44 was the first to successfully use systemic antibiotics in the treatment of Whipple's disease. In 1958, the use of
a peroral small-bowel biopsy specimen to perform the diagnosis of the
disease was reported 5.
In 1961, the rod-shaped structures in the intestinal mucosa and within
intestinal macrophages were demonstrated by electron microscopy to have
the structural characteristics of bacteria 56. Numerous
attempts have been made to identify the causative organism for
Whipple's disease. Many investigators have isolated a variety of
species in pure culture from intestinal biopsy specimens including
Haemophilus 60, Corynebacterium
7, and Streptococcus 10. These
conflicting results were probably due to the constant bacterial
colonization of the intestine. In 1991, Wilson et al. 63
reported on the 16S RNA gene of a novel bacterium. Indeed, the partial
sequence of this novel bacterium was identified in bacterial DNA
extracted from duodenal and lymph nodes biopsy specimens from patients
in whom Whipple's disease had been diagnosed according to
histopathological criteria. In 1992, these data were confirmed and the
causative bacterium constituted the novel, not-yet-validated taxon
"Tropheryma whippelii" to acknowledge Whipple's
contribution and to allude to the malabsorption caused by the disease
50. This result of PCR and sequence analysis has
classified the bacterium as belonging to the gram-positive
Actinomycetes clade. A successful attempt to culture the
causative organism was first reported in 1997 55, when
human macrophages inactivated by interleukin-4 were used to grow the
bacterium from two patients with culture-negative endocarditis, but
unfortunately, the work could not be pursued or reproduced
27. In 2000, we reported on the successful isolation and
establishment of a strain of Whipple's disease bacterium obtained from
the valve of a patient with blood culture-negative endocarditis 48.
 |
THE DISEASE |
Whipple's disease is considered a rare pathology, with less than
1,000 cases having been reported to date. In postmortem studies, the
frequency of the disease is quoted as being less than 0.1% 17. Males are more frequently affected than females
60. Indeed, 80% of the cases occur in males. All age
groups can contract the disease, although the 40- to 50-year-old age
group predominates and children are only extremely rarely affected
14, 17. The disease occurs worldwide, but most of the
patients are Caucasian 14. It has been speculated that
some kind of immune defect may predispose individuals to the
development of the disease 54. It appears also that a
certain genetic predisposition could be involved. Indeed, HLA-B-27 is
detectable in 28 to 44% of those suffering from the disease, while it
is found in only approximately 8% of the healthy population
18. Furthermore, even if Whipple's disease is not
familial, two set of brothers, a brother-sister pair, and a
father-daughter pair with the disorder have been reported 13, 16,
22, 46. This again suggests that Whipple's disease might be
associated with immunogenetic factors. In addition, most patients have
immune defects characterized by deficiency in the production of
interleukin-12 by monocytes macrophages associated with a reduced
capability to produce gamma interferon by T cells and subsequently to a
decreased activation and function of macrophages 39.
For a long time, Whipple's disease has been considered a
gastrointestinal disease. In reality, the clinical manifestations of
Whipple's disease are myriad and nonspecific. The various
manifestations of Whipple's disease are summarized in Table
1. Typical Whipple's disease is
characterized by a prodromal period of migratory polyarthritis, fatigue, weight loss, and anemia, followed by a progressive syndrome of
abdominal pain, distention, steatorrhea, and severe cachexia 9,
35). On physical examination, lymphadenopathy and hyperpigmentation are
frequent findings 19, 60. The spontaneous evolution of this disease is frequently long. During many years, progress is marked
by repeated remissions and relapses, with gradual worsening and
eventual death 29.
The central nervous system, lungs, heart, eyes, and skin may be
involved, and the disease may first manifest in these organs. Some
patients could present with fever of unknown origin, lymphadenopathy, and a sarcoidosis-like syndrome (W. O. Dobbins, Editorial, N. Engl. J. Med. 332:390-392, 1995). A recent study has shown that 15% of patients do not have gastrointestinal symptoms throughout their illness 60, and jejunal biopsy specimens may present
as normal on histopathological examination 37. Central
nervous system symptoms are frequent and varied. Perhaps in as many as 5% of all cases of Whipple's disease, the presentation is
neurological and the disease remains confined to the nervous system for
the most part of the evolution of the disease 2.
Irrespective of disease elsewhere in the body, the neurological
manifestations of Whipple's disease are known and sufficiently well
described to enable the recognition of some patterns which point to the diagnosis. Dementia, disturbances of ocular movements, abnormal involuntary movements, particularly myoclonus, and deranged function of
the hypothalamus are most often found. Epilepsy, focal cerebral signs,
ataxia, and parkinsonian and meningitic features may also be present
2, 4. Headaches are a very common symptom. It is not usual
to get involvement of the spinal cord or of muscle or peripheral nerve,
although myelopathy has been described 24. It should be
noted that the proportion of patients with asymptomatic central nervous
system infection is probably quite high, as indicated by the report of
von Herbay et al. 61 showing that 7 of 10 patients without
neurological symptoms nevertheless had cerebrospinal fluid findings
consistent with Whipple's disease. The ophthalmologic manifestations
are usually associated with central nervous system manifestations, but
are sometimes isolated 2. Uveitis, retinitis, keratitis,
optic neuritis, and papilloedema may be found 2. Cardiovascular manifestations are also frequent in patient's with Whipple's disease. Since the first report in 1952, cardiac involvement has been reported in 20 to 55% of patients 58-60,
whereas certain autopsy studies have shown an almost constant
involvement of at least one of the three cardiac layers
52. Constrictive pericarditis, endocarditis, myocarditis,
coronary arteritis, congestive heart failure, and sudden death have
been documented 29-31. Furthermore, Whipple's disease
endocarditis without gastrointestinal symptoms has been more and more
frequently described, and duodenal biopsy specimens of some of these
patients were negative by histopathology and PCR 8, 23.
Another characteristic finding in Whipple's disease is chronic cough,
which is probably a symptom of pleural involvement 17. New
manifestations of Whipple's disease, such as spondylodiscitis
1, prosthetic joint infection 20, intractable immune thrombocytopenic purpura 40, granulomatous
nephritis (I. Marie, F. Lecomte, and H. Levesque, Letter, Ann.
Intern. Med. 132:94-95, 2000), hypertrophic
osteoarthropathy 38, and hypopituitarism 6,
continue to be reported in the literature.
 |
THE AGENT |
The etiology and pathogenesis of Whipple's disease have
remained elusive for many years, even if a bacterial cause could have been suggested since the original description, as Whipple stated: "studied with 1/12 objective these sections show numbers of a rod-shaped organism (?)" 62. Since 1961, electron
microscopy studies had documented the presence of a bacterium in
involved tissues 56. The plasma membrane was surrounded by
a thin homogeneous wall, itself surrounded by a plasma membrane-like
structure, giving a trilamellar appearance (Fig.
1). The latter feature is more characteristic of gram-negative bacteria. Many laboratories have shown
a bacterium of 0.25 by 1 to 2 µm in infected tissues, both intracellularly and extracellularly. The Whipple's disease bacterium is present within a variety of cells, including macrophages, intestinal epithelial cells, lymphatic and capillary endothelial cells,
smooth-muscle cells, polymorphonuclear leukocytes, plasma cells, mast
cells, and even intraepithelial lymphocytes 3. The
intracellular bacteria are often intact in structure, which suggests
that these organisms may be intracellular pathogens, but it has also
been recognized as degraded to various degrees within macrophages
15. The difficulties experienced in isolating the
microorganism stimulated the application of molecular techniques to the
search and led to the identification of a single 16S RNA gene sequence
from small-bowel biopsy specimens of several patients with Whipple's
disease. Positive results have been obtained from various tissues
including the heart, vitreous fluid, peripheral blood cells, pleural
effusion cells, and cerebrospinal fluid by PCR gene amplification. By
16S RNA gene amplification, a study has suggested that the bacterium is
an environmental agent present especially in water, and it seems to be
a rather common environmental agent in certain geographic areas
34. This is in accordance with the phylogenetic
relationship with the Actinomycetes clade of this bacterium.
That could also explain the high proportion of farmers among patients
(14; R. M. J. Donaldson, Editorial, N. Engl. J. Med. 327:346-348, 1992). An oral infectious route of the
bacillus is then suspected. A possible carriage of the Whipple's
disease bacterium in the gastrointestinal tract has been suggested by
the fact that in a prospective blinded study by PCR of gastrointestinal
biopsy specimens of 105 patients without any sign of Whipple's
disease, the authors found positive results for 11.4% of the gastric
fluid specimens and 4.8% of the duodenal biopsy specimens (H. U. Ehrbar, P. Bauerfeind, F. Dutly, H. R. Koelz, and M. Altwegg,
Letter, Lancet, 353:2214, 1999). Furthermore, another recent
PCR study has shown positive rates of 35% for saliva from a random
sample of 40 healthy people (S. Street, H. D. Donoghue, and
G. H. Neild, Letter, Lancet 354:1178-1179, 1999). We
could then suspect that the Whipple's disease bacterium or closely
related bacteria are present in a substantial fraction of the
population in the absence of Whipple's disease, and it could be
speculated that it is an oral commensal organism or that it is
associated with currently unknown clinical manifestations. However, the data from these two studies should be confirmed, as
they are PCR based and the PCR was possibly contaminated. Nevertheless, when we tested sera from blood donor controls with no identified Whipple's disease, the majority (29 of 40) exhibited antibodies of the
immunoglobulin G(IgG) type to the Whipple's disease bacterium 48. This could be related to unspecific cross-reacting
antibodies or to a previous contact with the bacterium.
Whether the same bacterium causes all forms of Whipple's disease and
its multisystem manifestations remains to be determined. However,
sequencing of the nested PCR products obtained with primers derived
from the 16S-23S rRNA gene and domain III of the 23S rRNA gene has
revealed four different genotypes 26, 27. In the absence
of DNA-DNA hybridization data, it is uncertain whether the types found
represent subtypes of a single species or different but closely related
species. Now, with the possibility of cultivation of the Whipple's
disease bacterium, new isolates can be obtained, allowing a better
understanding of the physiopathology of the disease.
 |
DIAGNOSIS |
Nonspecific diagnosis.
Nonspecific biological findings
often include signs of chronic inflammation with an elevated
erythrocyte sedimentation rate and elevated C-reactive protein levels
60. Anemia is also frequently observed 60.
Leukocytosis, leukopenia, and eosinophilia can be noted in the sample
used for determination the white blood cell count, and signs of
malabsorption may occur 9, 19, 35, 60.
Specific diagnosis.
The specific tools for the diagnosis of
Whipple's disease are summarized in Table
2.
(i) Pathological examination.
If the disease is suspected on
the basis of the clinical profile, then duodenal biopsy specimens
provide the answer in the majority of cases. The confirmatory finding
is the presence of characteristic histological features on microscopic
examination. In typical Whipple's disease, the most severe changes are
seen in the small intestine and mesenteric lymph nodes, in which biopsy often reveals large, foamy macrophages. These macrophages were considered the hallmark of Whipple's disease and contain
intracytoplasmic granules that are positive on PAS staining; they were
then filled with either mucopolysaccharide or glycoprotein
25. These PAS-positive cells could also be detected in
practically all organs (colon, stomach, esophagus, gall bladder, liver,
pancreas, spleen, heart, lungs, kidneys, suprarenal glands, central
nervous system, serous membranes, blood vessels, and joints). However,
it is noteworthy that PAS-positive cells, which in the past were
considered pathognomonic of Whipple's disease, were seen not only in
healthy persons (in whom cells were few and their staining was faint)
but also in patients with infection due to Mycobacterium avium-M.
intracellulare 36, 53; Dobbins, Letter). The
distinction could be made by acid-fast staining, which is positive for
patients infected with M. avium and negative for those with
Whipple's disease. In one case, a pulmonary infiltrate in a patient
with AIDS also contained macrophages with PAS-positive granules which
correspond in reality to a gram-positive coccobacillus
(Rhodococcus equi) (H. H. Wang, D. Tollerud, D. Danar,
P. Hanff, K. Gottesdiener, and S. Rosen, Letter, N. Engl. J. Med.
314:1577-1578, 1986).
With the successful isolation and cultivation of the Whipple's disease
agent, generation of polyclonal antibodies to the bacterium in the
mouse and the rabbit could be realized. By using these antibodies with
immunohistology, we could detect the bacterium in tissues, as in a
patient with Whipple's disease endocarditis 48 and a
biopsy specimen of the small intestine, but the specificities of these
antibodies remain to be shown with a larger series of patients
(unpublished data). We have now designed monoclonal antibodies which
are species specific and which could probably be used in the near
future (unpublished data).
(ii) Culture.
Attempts to cultivate the organism over the
years have been considered unsuccessful, even if a culture of the
causative organism was reported, because, unfortunately, the work could
not be pursued, reproduced, or confirmed and no strain is available
27, 55. Our work has shown that a culture can be performed
by using the human fibroblast cells lines HEL and MRC5, which are grown
in minimal essential medium with 10% fetal calf serum and 2mM
L-glutamine without antibiotics, and a control strain is
available for the scientific community 48. By observing
the flask monolayer with an inverted microscope, a cytopathic effect
could be observed after several weeks; small coarse dark inclusions and
large coarse round structures were detected within cells. Within this
system, the generation time had been evaluated to be about 18 days.
Cells appeared to be filled with coarse PAS-positive conglomerates and short slender PAS-positive rods (Fig. 2).
Culture may then be performed with a biopsy sample or a fluid aspirate
by the centrifugation shell vial technique with human fibroblast cell
line HEL 48. It took 6 weeks before a cytopathic effect
was observed by this technique 48. However,
immunodetection or PCR could be performed, and the growth of the
Whipple's disease bacterium in the cells could be detected earlier.
All attempts of subculture on axenic medium with chocolate and Columbia
sheep blood agars incubated at 32 and 37°C under 5% CO2
in a microaerophilic and anaerobic atmosphere and with cell culture
medium and cell culture medium with lysates of HEL cells incubated at
32 and 37°C under 5% CO2 were unsuccessful
48. The limits of culture are the generation time of the
bacteria, the necessity to have qualified personnel, and laboratory
technical capacities. If the 18-day minimal doubling time is confirmed
with other cell lines, it will explain why the bacterium could not be
propagated either in human macrophages, which have a short life time in
vitro, or in multiplying cells, which may dilute the bacterium.
(iii) PCR gene amplification.
On the basis of sequence
analysis of the 16S rRNA gene, several diagnostic PCR assays targeting
various parts of this gene were established 26. PCR has
become an important diagnostic tool for establishment of the diagnosis
of Whipple's disease, especially in patients with unusual
presentations and if the diagnosis cannot be confirmed histologically
(Dobbins, Letter). DNA amplification methods are considerably more
sensitive, thus facilitating the laboratory diagnosis and monitoring of
both typical and atypical cases of Whipple's disease. For all these
situations, research on the Whipple's disease bacterium can now be
performed on the basis of PCR with biopsy specimens tissue (i.e.,
duodenum, ileum, jejunum, lymph nodes, cardiac valve, cardiac muscle,
or synovium) or fluid aspirate (i.e., gastric fluid, cerebrospinal
fluid, pleural effusion, synovial fluid, bone marrow, or vitreous
fluid) or by analysis of peripheral blood 32, 45, 47;
Dobbins, Letter; S. A. Misbah, D. Stirzaker, B. Ozols, A. Franks,
and N. Mapstone, Letter, Q. J. Med. 92:61, 1999; C. Muller, C. Stain, and O. Burghuber, Letter, Lancet 341:701,
1993). The sequences of the PCR primers available for the diagnosis of
Whipple's disease are summarized in Table
3 12, 21, 26, 27, 28, 42, 47, 50,
51, 61. One of the important limits of PCR is its specificity,
due to several problems. First, positive PCR results have been found in
duodenal biopsy specimens, saliva, and gastric juice in people without
clinical signs of Whipple's disease (Muller, C. Stain, and O. Burghuber, Letter, Lancet 341:701, 1993). Second, if the
Whipple's disease bacterium is an environmental agent commonly found
in water, PCR contamination may occur easily. Third, amplified bands of
the presumably appropriate fragment length may be nonspecific.
Therefore, a second step, direct sequencing or a hybridization step, is
necessary after PCR to confirm the identities of the amplified
products. Thus, interpretation of PCR results without histological
confirmation should be regarded with prudence and in light of the
clinical features (Muller et al., Letter). Although hybridization and
sequencing of PCR products may provide further evidence for the
presence of the DNA of the Whipple's disease bacterium, these
techniques are rather tedious and time-consuming and do not reliably
exclude the possibility of amplicon carryover contamination. However,
an additional species-specific PCR with an independent target of the
Whipple's disease bacterium might provide the necessary confirmation
within a reasonable time frame for specimens with inconclusive
histopathological findings. Hinrikson et al. 26 have
recently proposed performance of such a study by nested PCR, targeting
a part of 23S rRNA gene domain III of the Whipple's disease bacterium.
This technique seems to be sensitive and specific. Furthermore,
sequence data for 23S rRNA gene domain III amplicons were included in a
proposed classification system for molecular variants 26.
Very recently, a new PCR system targeting a heat shock protein
(hsp65) has been described 42. In our
laboratory, we have begun to sequence new genes such as rpoB
(RNA polymerase beta subunit-encoding gene) which could be a useful
tool for identification (unpublished data).
PCR may also be used for the monitoring of Whipple's disease.
Indeed, a negative result by PCR may predict a low likelihood of clinical relapse. A result that remains positive despite
therapy may be associated with a poor clinical outcome 47,
61.
 |
THE FUTURE |
The disease.
Whipple's disease is considered rare,
and postmortem studies have estimated the disease rate to be less than
0.1% 17. Paradoxically, by PCR, first studies have shown
that the frequency of the Whipple's disease bacterium is high in
healthy people as well as in the environment. Several hypotheses could
be suggested to explain this discrepancy. The disease is rare,
occurring only in patients with particular risk factors or
genetic susceptibility. Some specific pathogenic strains of the
Whipple's disease bacterium may cause the disease and others may not.
The frequency of the disease could have been widely underestimated.
Indeed, with the development of diagnosis by PCR, new clinical
manifestations due to the Whipple's disease bacterium have been
described with an increased frequency, such as endocarditis and
uveitis. In addition, the characterization of the Whipple's disease
bacterium and the associated diseases will be improved, as for
endocarditis, for which two entities seem to exist: one in which valve
involvement is a part of the disease and another in which it is the
unique symptom 23, 48, 49. Finally, Whipple's disease
could be only one manifestation of a much more frequent disease
currently unidentified. The increasing number of available tools may
help to identify such new clinical entities.
Serology.
Serological tests could be highly useful since a
single blood sample could be used to make the diagnosis and could be
life saving by allowing the institution of appropriate therapy. Now, with the possible cultivation of the Whipple's disease bacterium, some
antigens could be produced to develop a serological test that would
allow easier diagnosis of this disease that is currently difficult to
diagnose. By using a monolayer infected with the bacillus of Whipple's
disease, an immunofluorescence serological test has been developed
48. The serum samples are diluted in phosphate-buffered
saline containing 3% nonfat dry milk, and the IgG and IgM titers are
determined. To remove IgG, rheumatoid factor adsorbant is added before
the determination of the IgM titer. Using this technique, we examined
sera from 9 patients with Whipple's disease and 40 control subjects
48. When a cutoff value of 1:100 was selected, IgG
antibodies against the bacillus were detected in the serum samples of
all nine patients with Whipple's disease, as well as almost 75% of
the samples from the control subjects. The specificity of the presence
of IgM antibodies was greater; using a cutoff value of 1:50, we found
that the results were positive for 7 of 9 patients with Whipple's
disease, whereas they were positive for 3 of 40 control subjects. Also,
higher titers of IgM antibodies (
1:400) were present in three of
seven patients with classic Whipple's disease and in both patients
with Whipple's disease endocarditis but in none of the control
subjects 48. The high frequency of IgG antibodies against
the Whipple's disease isolate suggest that this pathogen is
ubiquitous, causing illness only occasionally, perhaps because of
differences in virulence among the strains or in host factors or as a
result of the patient's exposure to other immunologically
cross-reacting microorganisms. Large-scale studies are necessary to
confirm these results. Moreover, Western blotting, by which the
discriminative potential of proteins may be determined by a scoring
method, may contribute to a specific diagnosis.
Monoclonal antibodies.
The culture of the Whipple's
disease bacterium could allow the production of monoclonal antibodies.
Monoclonal antibodies may provide a specific, simple, rapid, and
low-cost tool that could be applied to tissues for the identification
of the Whipple's disease bacterium and infection due to the
microorganism. They are being developed in our laboratory.
Sequencing.
The establishment of a strain of the Whipple's
disease bacterium has allowed its purification. It will also make it
possible to start genetic studies. Thus, new target sequences will be
available to perform PCR assays and to study the presence of molecular
variants of the Whipple's disease bacterium. Sequencing would help
with further epidemiological and clinical studies with the Whipple's disease bacterium and associated diseases and also with
characterization of the mechanism of pathogenicity.
Antibiotic susceptibility testing.
Almost all antibiotics have
been used for the treatment of Whipple's disease. However, the optimum
treatment for Whipple's disease remains controversial with respect to
both the choice of drug and the duration of treatment. Care must be
taken to use those antibiotics that readily cross the blood-brain
barrier, as organisms sequestered in the central nervous system can be a cause of disease recrudescence 57. The recommended
treatment currently is daily parenteral administration of streptomycin
(1 g) and benzylpenicillin (penicillin G; 1.2 × 10b
units) over a period of 14 days, followed by oral co-trimoxazole (trimethoprim-sulfamethoxazole at 160/800 mg) twice daily for 1 year
57. However, it is documented that central nervous
symptoms can also develop during its use 11. Dykman et al.
16 have suggested that this may be related to the fact
that despite the high intracellular concentrations achieved with the
use of this drug, it is only bacteriostatic. They have also added that
the use of bactericidal drugs, such as ceftriaxone, initially followed by the use of an oral cephalosporin, such as cefixime, may be the most
prudent strategy. With the recent possibility of cultivation of the
Whipple's disease bacterium, tests for determination of the resistance
of the bacterium to antibiotics could be developed and will allow
a better definition of an antibiotic therapy strategy.
Pathophysiology.
With the culture of the Whipple's disease
bacterium, pathophysiology studies can begin. An animal model which
closely mimics pathological mechanisms of Whipple's disease should be
developed. It is first necessary to determine the method of inoculation
(intravenous, intraperitoneal, or another way) and the kind of animal
to be used, mice (immunocompetent and/or immunosuppressed), guinea
pigs, rabbits, rats, or some other animal. An experimental model with monocytes/macrophages could also be developed, leading to a better understanding of the phagocytosis and the survival of the Whipple's disease bacterium in these cells, as have already been described 55.
 |
CONCLUSION |
For numerous years, Whipple's disease was considered to
be due to a bacterium which was responsible for a gastrointestinal disease. In reality, this bacterium seems to be more ubiquitous than
once believed, and various sites of localization of Whipple's disease
without gastrointestinal symptoms have recently been described. At
present, with the development of new tools for performance of the
diagnosis of Whipple's disease, such as PCR and culture, a new era is
emerging. In the future, one can expect descriptions of a spectrum of
new diseases due to the Whipple's disease bacterium. New tools
such as monoclonal antibodies and serology could also be developed to
improve the diagnosis. It is yet the case for Whipple's disease
endocarditis. Furthermore, with the culture of the bacterium,
pathophysiology studies could help us to better understand this complex disease.
 |
ACKNOWLEDGMENT |
We are indebted to Bernard La Scola for the picture
demonstrating T. whippelii by electron microscopy and PAS staining.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité des
Rickettsies, CNRS: UPRESA 6020, Faculté de Médecine,
Université de la Méditerranée, 27 Blvd. Jean Moulin,
13385 Marseille cedex 05, France. Phone: (33).04.91.38.55.17. Fax:
(33).04.91.83.03.90. E-mail: DidierRaoult{at}univ.mrs.fr.
 |
REFERENCE |
| 1.
|
Altwegg, M.,
A. Fleisch-Marx,
D. Goldenberg,
S. Hailemariam,
A. Schaffner, and R. Kissling.
1996.
Spondylodiscitis caused by Tropheryma whippelii.
Schweiz. Med. Wochenschr.
126:1495-1499[Medline].
|
| 2.
|
Anderson, M.
2000.
Neurology of Whipple's disease.
J. Neurol. Neurosurg. Psychiatry
68:2-5[Free Full Text].
|
| 3.
|
Austin, L. L., and W. O. Dobbins.
1982.
Intraepithelial leukocytes of the intestinal mucosa in normal man and in Whipple's disease: a light- and electron-microscopic study.
Dig. Dis. Sci.
27:311-320[CrossRef][Medline].
|
| 4.
|
Averbuch-Heller, L.,
G. W. Paulson,
R. B. Daroff, and R. J. Leigh.
1999.
Whipple's disease mimicking progressive supranuclear palsy: the diagnostic value of eye movement recording.
J. Neurol. Neurosurg. Psychiatry
66:532-535[Abstract/Free Full Text].
|
| 5.
|
Bolt, R. J.,
H. M. Pollard, and L. Tandaert.
1958.
Transoral small bowel biopsy as an aid in the diagnosis of malabsorption states.
N. Engl. J. Med.
259:32-34.
|
| 6.
|
Brandle, M.,
P. Ammann,
G. A. Spinas,
F. Dutly,
R. L. Galeazzi,
C. Schmid, and M. Altwegg.
1999.
Relapsing Whipple's disease presenting with hypopituitarism.
Clin. Endocrinol. (Oxford)
50:399-403[Medline].
|
| 7.
|
Caroli, J.,
C. Julien, and B. Bonneville.
1965.
La maladie de Whipple. Revue générale et acquisitions récentes.
Rev. Franc. Etudes Clin. Biol.
X:362-380.
|
| 8.
|
Celard, M.,
G. de Gevigney,
S. Mosnier,
P. Buttard,
Y. Benito,
J. Etienne, and F. Vandenesch.
1999.
Polymerase chain reaction analysis for diagnosis of Tropheryma whippelii infective endocarditis in two patients with no previous evidence of Whipple's disease.
Clin. Infect. Dis.
29:1348-1349[Medline].
|
| 9.
|
Chears, W. C.,
M. D. Hargrove,
J. V. Verner,
A. G. Smith, and J. M. Ruffin.
1961.
Whipple's disease. A review of twelve patients from one service.
Am. J. Med.
30:226-234.
|
| 10.
|
Clancy, R. L.,
W. A. Tomkins,
T. J. Muckle,
H. Richardson, and W. E. Rawls.
1975.
Isolation and characterization of an aetiological agent in Whipple's disease.
Br. Med. J.
3:568-570.
|
| 11.
|
Cooper, G. S.,
E. W. Blades,
B. F. Remler,
R. A. Salata,
K. W. Bennert, and G. H. Jacobs.
1994.
Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime.
Gastroenterology
106:782-786[Medline].
|
| 12.
|
Dauga, C.,
I. Miras, and P. A. Grimont.
1997.
Strategy for detection and identification of bacteria based on 16S RNA genes in suspected cases of Whipple's disease.
J. Med. Microbiol.
46:340-347[Abstract].
|
| 13.
|
Dobbins, W. O.
1987.
HLA antigens in Whipple's disease.
Arthritis Rheum.
30:102-105[Medline].
|
| 14.
|
Dobbins, W. O.
1987.
Whipple's disease.
Charles C Thomas, Springfield, III.
|
| 15.
|
Dobbins, W. O., and H. Kawanishi.
1981.
Bacillary characteristics in Whipple's disease: an electron microscopic study.
Gastroenterology
80:1468-1475[Medline].
|
| 16.
|
Dykman, D.,
B. A. Cuccherini,
I. Fuss,
L. Blum, and R. S. Wouters.
2000.
Whipple's disease in a father-daughter.
Dig. Dis. Sci.
44:2542-2544.
|
| 17.
|
Enzinger, F. M., and E. B. Helwig.
1963.
Whipple's disease: a review of the literature and report of fifteen patients.
Virchows Arch. Pathol. Anat.
336:238-269[CrossRef].
|
| 18.
|
Feldman, M.
1986.
Whipple's disease.
Am. J. Med. Sci.
291:56-67[CrossRef][Medline].
|
| 19.
|
Fleming, J. L.,
R. H. Wiesner, and R. G. Shorter.
1988.
Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients.
Mayo Clin. Proc.
63:539-551[Medline].
|
| 20.
|
Fresard, A.,
C. Guglielminotti,
P. Berthelot,
A. Ros,
F. Farizon,
C. Dauga,
H. Rousset, and F. Lucht.
1996.
Prosthetic joint infection caused by Tropheryma whippelii.
Clin. Infect. Dis.
22:575-576[Medline].
|
| 21.
|
Goldenberger, D.,
A. Kunzli,
P. Vogt,
R. Zbinden, and M. Altwegg.
1997.
Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing.
J. Clin. Microbiol.
35:2733-2739[Abstract].
|
| 22.
|
Gross, J. B.,
E. E. Wollaeger,
W. G. Sauer,
K. A. Huizenga,
D. C. Dahlin, and M. H. Power.
1959.
Whipple's disease report of four cases, including two in brothers, with observation on pathologic physiology, diagnosis, and treatment.
Gastroenterology
36:65-93[Medline].
|
| 23.
|
Gubler, J. G.,
M. Kuster,
F. Dutly,
F. Bannwart,
M. Krause,
H. P. Vogelin,
G. Garzoli, and M. Altwegg.
1999.
Whipple endocarditis without overt gastrointestinal disease: report of four cases.
Ann. Intern. Med.
131:112-116[Abstract/Free Full Text].
|
| 24.
|
Helliwell, T.,
R. Appleton,
N. Mapstone,
J. Davidson, and K. Walsh.
2000.
Dermatomyositis and Whipple's disease.
Neuromusc. Disord.
10:46-51[CrossRef][Medline].
|
| 25.
|
Hendrix, J. P.,
B. Black-Schaffer,
R. W. Withers, and P. Handler.
1950.
Whipple's intestinal lipodystrophy. Report of four cases and discussion of possible pathogenic factors.
Arch. Intern. Med.
85:91-131[CrossRef].
|
| 26.
|
Hinrikson, H. P.,
F. Dutly, and M. Altwegg.
2000.
Evaluation of a specific nested PCR targeting domain III of the 23S rRNA gene of "Tropheryma whippelii" and proposal of a classification system for its molecular variants.
J. Clin. Microbiol.
38:595-599[Abstract/Free Full Text].
|
| 27.
|
Hinrikson, H. P.,
F. Dutly,
S. Nair, and M. Altwegg.
1999.
Detection of three different types of `Tropheryma whippelii' directly from clinical specimens by sequencing, single-strand conformation polymorphism (SSCP) analysis and type-specific PCR of their 16S-23S ribosomal intergenic spacer region.
Int. J. Syst. Bacteriol.
49(Pt. 4):1701-1706[CrossRef][Medline].
|
| 28.
|
Hinrikson, H. P.,
F. Dutly, and M. Altwegg.
1999.
Homogeneity of 16S-23S ribosomal intergenic spacer regions of Tropheryma whippellii in Swiss patients with Whipple's disease.
J. Clin. Microbiol.
37:152-156[Abstract/Free Full Text].
|
| 29.
|
James, T. N., and B. H. Bulkley.
1983.
Abnormalities of the coronary arteries in Whipple's disease.
Am. Heart J.
105:481-491[CrossRef][Medline].
|
| 30.
|
Khairy, P., and A. F. Graham.
1996.
Whipple's disease and the heart.
Can. Cardiol.
12:831-834.
|
| 31.
|
Kloos, K.
1939.
Über eine eigenartige Fettresorptionsstörung und ihre Beziehung zur Sprue.
Arch. Pathol. Anat.
304:625-658.
|
| 32.
|
Lowsky, R.,
G. L. Archer,
G. Fyles,
M. Minden,
J. Curtis,
H. Messner,
H. Atkins,
B. Patterson,
B. M. Willey, and A. McGeer.
1994.
Brief report: diagnosis of Whipple's disease by molecular analysis of peripheral blood.
N. Engl. J. Med.
331:1343-1346[Free Full Text].
|
| 33.
|
Maiwald, M.,
A. von Herbay,
P. W. Lepp, and D. A. Relman.
2000.
Organization, structure, and variability of the rRNA operon of the Whipple's disease bacterium (Tropheryma whippelii).
J. Bacteriol
182:3292-3297[Abstract/Free Full Text].
|
| 34.
|
Maiwald, M.,
F. Schuhmacher,
H. J. Ditton, and A. von Herbay.
1998.
Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii).
Appl. Environ. Microbiol
64:760-762[Abstract/Free Full Text].
|
| 35.
|
Maizel, H.,
J. M. Ruffin, and W. O. Dobbins.
1970.
Whipple's disease: a review of 19 patients from one hospital and a review of the literature since 1950.
Medicine (Baltimore)
49:175-205[Medline].
|
| 36.
|
Maliha, G. M.,
K. S. Hepps,
D. M. Maia,
K. R. Gentry,
A. E. Fraire, and R. W. Goodgame.
1991.
Whipple's disease can mimic chronic AIDS enteropathy.
Am. J. Gastroenterol.
86:79-81[Medline].
|
| 37.
|
Mansbach, C. M.,
J. D. Shelburne,
R. D. Stevens, and W. O. Dobbins.
1978.
Lymph-node bacilliform bodies resembling those of Whipple's disease in a patient without intestinal involvement.
Ann. Intern. Med.
89:64-66.
|
| 38.
|
Marie, I.,
H. Levesque,
M. H. Levade,
N. Cailleux,
F. Lecomte,
A. Francois,
J. Metayer,
E. Lerebours, and H. Courtois.
1999.
Hypertrophic osteoarthropathy can indicate recurrence of Whipple's disease.
Arthritis Rheum.
42:2002-2006[CrossRef][Medline].
|
| 39.
|
Marth, T.,
M. Neurath,
B. A. Cuccherini, and W. Strober.
1997.
Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease.
Gastroenterology
113:442-448[CrossRef][Medline].
|
| 40.
|
Misbah, S. A.,
B. Ozols,
A. Franks, and N. Mapstone.
1997.
Whipple's disease without malabsorption: new atypical features.
O. J. Med.
90:765-772.
|
| 41.
|
Morgan, A. D.
1961.
The first recorded case of Whipple's disease.
Gut
2:370-372.
|
| 42.
|
Morgenegg, S.,
F. Dutly, and M. Altwegg.
2000.
Cloning and sequencing of a part of the heat shock protein 65 (hsp65) gene of Tropheryma whippelii and its use for the detection of Tropheryma whippelii in clinical specimens by PCR.
J. Clin. Microbiol.
38:2248-2253[Abstract/Free Full Text].
|
| 43.
|
Oliver-Pasqual, E.,
J. Galan, and A. Oliver-Pasqual.
1947.
Un case de lipodistrofica intestinal con lesions gangliones mesentericas de granulomatosis lipofagica (Enfermed de Whipple).
Rev. Esp. Enferm. Apar. Dig.
6:213-226.
|
| 44.
|
Paulley, J. W.
1952.
A case of Whipple's disease (intestinal lipodystrophy).
Gastroenterology
22:128-133[Medline].
|
| 45.
|
Pron, B.,
C. Poyart,
E. Abachin,
T. Fest,
C. Belanger,
C. Bonnet,
P. Capelle,
J. F. Bretagne,
A. Fabianek,
L. Girard,
H. Hagege, and P. Berche.
1999.
Diagnosis and follow-up of Whipple's disease by amplification of the 16S rRNA gene of Tropheryma whippelii.
Eur. J. Clin. Microbiol. Infect. Dis.
18:62-65[CrossRef][Medline].
|
| 46.
|
Puite, R., and H. Teslik.
1955.
Whipple's disease.
Am. J. Med.
19:383-400[CrossRef][Medline].
|
| 47.
|
Ramzan, N. N.,
E. J. Loftus,
L. J. Burgart,
M. Rooney,
K. P. Batts,
R. H. Wiesner,
D. N. Fredricks,
D. A. Relman, and D. H. Persing.
1997.
Diagnosis and monitoring of Whipple disease by polymerase chain reaction.
Ann. Intern. Med.
126:520-527[Abstract/Free Full Text].
|
| 48.
|
Raoult, D.,
M. L. Birg,
B. La Scola,
P. E. Fournier,
M. Enea,
H. Lepidi,
V. Roux,
J. C. Piette,
F. Vandenesch,
D. Vital-Durand, and T. J. Marrie.
2000.
Cultivation of the bacillus of Whipple's disease.
N. Engl. J. Med.
342:620-625[Abstract/Free Full Text].
|
| 49.
|
Raoult, D.
1999.
Afebrile blood culture-negative endocarditis.
Ann. Intern. Med.
131:144-146[Free Full Text].
|
| 50.
|
Relman, D. A.,
T. M. Schmidt,
R. P. MacDermott, and S. Falkow.
1992.
Identification of the uncultured bacillus of Whipple's disease.
N. Engl. J. Med.
327:293-301[Abstract].
|
| 51.
|
Rickman, L. S,
W. R. Freeman,
W. R. Green,
S. T. Feldman,
J. Sullivan,
V. Russack, and D. A. Relman.
1995.
Brief report: uveitis caused by Tropheryma whippelii (Whipple's bacillus).
N. Engl. J. Med.
332:363-366[Free Full Text].
|
| 52.
|
Rose, A. G.
1978.
Mitral stenosis in Whipple's disease.
Thorax
33:500-503[Abstract].
|
| 53.
|
Roth, R. I.,
R. L. Owen,
D. F. Keren, and P. A. Volberding.
1985.
Intestinal infection with Mycobacterium avium in acquired immune deficiency syndrome (AIDS). Histological and clinical comparison with Whipple's disease.
Dig. Dis. Sci.
30:497-504[CrossRef][Medline].
|
| 54.
|
Schneider, T.,
A. Stallmach,
A. von Herbay,
T. Marth,
W. Strober, and M. Zeltz.
1998.
Treatment of refractory Whipple's disease with interferon- .
Ann. Intern. Med.
129:875-877.
|
| 55.
|
Schoedon, G.,
D. Goldenberger,
R. Forrer,
A. Gunz,
F. Dutly,
M. Hochli,
M. Altwegg, and A. Schaffner.
1997.
Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii.
J. Infect. Dis.
176:672-677[Medline].
|
| 56.
|
Silva, M. T.,
P. M. Macedo, and N. J. Moura.
1985.
Ultrastructure of bacilli and the bacillary origin of the macrophagic inclusions in Whipple's disease.
J. Gen. Microbiol.
131:1001-1013[Medline].
|
| 57.
|
Singer, R.
1998.
Diagnosis and treatment of Whipple's disease.
Drugs
55:699-704[CrossRef][Medline].
|
| 58.
|
Tytgat, G. N.,
J. L. Hoogendijk,
D. Agenant, and P. T. Schellekens.
1977.
Etiopathogenetic studies in a patient with Whipple's disease.
Digestion
15:309-321[CrossRef][Medline].
|
| 59.
|
Upton, A. C.
1952.
Histochemical investigation of the mesenchymal lesions in Whipple's disease.
Am. J. Clin. Pathol.
22:755-764.
|
| 60.
|
Vital-Durand, D.,
C. Lecomte,
P. Cathebras,
H. Rousset, and P. Godeau.
1997.
Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Societe Nationale Francaise de Medecine Interne.
Medicine (Baltimore)
76:170-184[CrossRef][Medline].
|
| 61.
|
von Herbay, A.,
H. J. Ditton,
F. Schuhmacher, and M. Maiwald.
1997.
Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid.
Gastroenterology
113:434-441[CrossRef][Medline].
|
| 62.
|
Whipple, G. H.
1907.
A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues.
Bull. Johns Hopkins Hosp.
198:383.
|
| 63.
|
Wilson, K. H.,
R. Blitchington,
R. Frothingham, and J. A. Wilson.
1991.
Phylogeny of the Whipple's-disease-associated bacterium.
Lancet
338:474-475[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, January 2001, p. 1-8, Vol. 8, No. 1
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.1.1-8.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Desnues, B., Raoult, D., Mege, J.-L.
(2005). IL-16 Is Critical for Tropheryma whipplei Replication in Whipple's Disease. J. Immunol.
175: 4575-4582
[Abstract]
[Full Text]
-
Boulos, A., Rolain, J. M., Mallet, M. N., Raoult, D.
(2005). Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium. J Antimicrob Chemother
55: 178-181
[Abstract]
[Full Text]
-
Drevets, D. A., Leenen, P. J. M., Greenfield, R. A.
(2004). Invasion of the Central Nervous System by Intracellular Bacteria. Clin. Microbiol. Rev.
17: 323-347
[Abstract]
[Full Text]
-
Boulos, A., Rolain, J.-M., Raoult, D.
(2004). Antibiotic Susceptibility of Tropheryma whipplei in MRC5 Cells. Antimicrob. Agents Chemother.
48: 747-752
[Abstract]
[Full Text]
-
Fenollar, F., Birg, M.-L., Gauduchon, V., Raoult, D.
(2003). Culture of Tropheryma whipplei from Human Samples: a 3-Year Experience (1999 to 2002). J. Clin. Microbiol.
41: 3816-3822
[Abstract]
[Full Text]
-
Bosman, C., Boldrini, R., Borsetti, G., Morelli, S., Paglia, M. G., Visca, P.
(2002). Sicca Syndrome Associated with Tropheryma whipplei Intestinal Infection. J. Clin. Microbiol.
40: 3104-3106
[Abstract]
[Full Text]
-
Ghigo, E., Capo, C., Aurouze, M., Tung, C.-H., Gorvel, J.-P., Raoult, D., Mege, J.-L.
(2002). Survival of Tropheryma whipplei, the Agent of Whipple's Disease, Requires Phagosome Acidification. Infect. Immun.
70: 1501-1506
[Abstract]
[Full Text]